Data on 22,694 women showed higher semaglutide uptake across contraceptive types. Lead author Mille Dybdal Bager warns the link is not cause and effect.
Recap by typeshit. Full story at Healio.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
An indirect comparison shown at EASD 2026 put orforglipron ahead of Rybelsus at 52 weeks. GlobalData's analyst says head-to-head trials are still needed.
A clinic explainer sorting the brand names, Ozempic and Wegovy versus Mounjaro and Zepbound, and how each drug works.
Loading…